Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. [electronic resource]
Producer: 20081210Description: 1855-60 p. digitalISSN:- 1879-0852
- Antigens, CD34 -- metabolism
- Antineoplastic Agents -- administration & dosage
- Benzamides
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Exons
- Female
- Gastrointestinal Stromal Tumors -- drug therapy
- Humans
- Imatinib Mesylate
- Immunohistochemistry
- Kaplan-Meier Estimate
- Male
- Mutation -- genetics
- Piperazines -- administration & dosage
- Proto-Oncogene Proteins c-kit -- genetics
- Pyrimidines -- administration & dosage
- Receptor, Platelet-Derived Growth Factor alpha -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.